Purpose of review Patients with type 1 diabetes (T1D) are typically viewed as lean
individuals. However, recent reports showed that their obesity rate surpassed that of the …

Obesity affects large numbers of patients with type 1 diabetes (T1D) across their lifetime,
with rates ranging between 2.8% and 37.1%. Patients with T1D and obesity are …

Insulin therapy (IT) is initiated for patients with type 2 diabetes mellitus when glycaemic
targets are not met with diet and other hypoglycaemic agents. The initiation of IT improves …

Background: The majority of patients with type 2 diabetes mellitus (T2DM) are overweight or
obese. Obesity is a significant risk factor for increased morbidity and mortality in people with …

Diabetes mellitus is the global health issue and become an alarming threat in the modern
era where human lifestyle gets compromised with modernization. According to the latest …

Aims This study assessed the efficacy and safety of once‐daily insulin initiation using insulin
detemir (detemir) or insulin glargine (glargine) added to existing metformin in type 2 …

Targeting body weight, as an alternative model to targeting hemoglobin A 1c, is emerging as
a viable and potentially cost-effective approach to diabetes management in clinical practice …

Insulin detemir (Levemir®) is a long-acting insulin analogue indicated for use as basal
insulin therapy in patients with type 1 or 2 diabetes mellitus. The protracted action of insulin …

There is a clinical rationale for a basal insulin with a predictable action and low inter‐and
intra‐individual variability coupled with an improved side effect and metabolic profile. Since …

Aim: The aim of this trial was to evaluate the efficacy and safety of the combination of once‐
daily insulin detemir (IDet) and sitagliptin (SITA) versus SITA±sulphonylurea (SU), both in …